GWM
BEAM icon

Geneos Wealth Management’s Beam Therapeutics BEAM Stock Holding History

Geneos Wealth Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25
Closed – – 2057
2022
Q2 		$0 Buy
+25
New +$994 ﹤0.01% 2594
2021
Q2 		– Sell
-58
Closed -$4K – 2870
2021
Q1 		$4K Buy
58
+40
+222% +$3.81K ﹤0.01% 2699
2020
Q4 		$1K Buy
+18
New +$885 ﹤0.01% 2763

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Geneos Wealth Management's BEAM Position: Q3 2022 in Review

Geneos Wealth Management sold out of Beam Therapeutics (BEAM) in Q3 2022, closing a stake of 25 shares.

Geneos Wealth Management first reported a position in BEAM in Q4 2020 and held it in 3 quarters. The position peaked at $4K in Q1 2021. 224 funds tracked by Wall St. Rank hold BEAM as of Q3 2022.

  • Geneos Wealth Management reported no remaining Beam Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Geneos Wealth Management sold 25 Beam Therapeutics shares in Q3 2022.
  • Geneos Wealth Management first reported a position in Beam Therapeutics in Q4 2020 and held it in 3 quarters.
  • Geneos Wealth Management's Beam Therapeutics position peaked at $4K in Q1 2021.
  • 224 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2022.

Based on Geneos Wealth Management's 13F filing for Q3 2022, filed 14 Nov 2022.